Developer docs
API playgroundTry for free, no card

Search company profiles

Fairmount Funds Management

Full company profile

uuid0000cr2

Namestring
Fairmount Funds Management
Legal namestring
Fairmount Funds Management LLC
Websiteurl
fairmountfunds.com
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotechnology venture capital, life science investing, healthcare investment management, therapeutic development funding, clinical-stage equity financing
Industry1 code
1Venture Debt Providers
CodeFSANAAALPrimaryYes
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Finance Services6199
Product category
Healthcare Venture Capital Investment Management
Social media profiles1 record
Revenue model1 record
1Investment Returns and Capital Gains
TypeLicensing Royalties
Description

Generates returns through equity investments in biotechnology and life science companies, including venture capital funding rounds, public market investments, and strategic financing arrangements.

fairmount.com
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Fairmount Funds Management is a Philadelphia-based investment firm dedicated to providing venture capital and strategic financing to biotechnology and life science companies pursuing novel therapeutic treatments. The firm deploys capital through seed investments, private placements, Series A financings, and secondary-market share sales, while also engaging actively in portfolio governance through board representation and voting agreements supporting strategic transactions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Fairmount Funds Management is a Philadelphia-based investment firm that does not offer a technology product or service platform. It is dedicated to investing in promising new therapies pursued by biotechnology and life science companies, providing capital to support the development of therapeutic candidates across various stages of development.

Product and service1 record
1Biotechnology and life science venture capital investment services
CategoryVenture Capital Investment Services
Description

Equity capital deployment into clinical-stage and commercial-stage biotechnology and life science companies pursuing novel therapeutic treatments, provided to biotech issuers and their boards as direct equity investments through seed, private placement, Series A, and other structured financings.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Venrock Healthcare Capital Partners
TypeDirect peer
Description

Healthcare-focused venture capital firm that co-invested alongside Fairmount in co-founding Korsana Biosciences. Highly comparable as a biotech/life science specialist with similar investment stage and sector mandate.

2RA Capital Management
TypeDirect peer
Description

Healthcare-focused crossover fund that invests across public and private biotech companies. Comparable in sector focus, ability to participate across financing stages, and lead private placements in therapeutic developers.

3Baker Bros. Advisors
TypeDirect peer
Description

Biotech-focused long-only investment manager with deep life sciences specialization. Comparable in vertical focus on therapeutic developers and willingness to take concentrated, long-duration positions.

4OrbiMed Advisors
TypeBroad incumbent
Description

Large, established healthcare investment platform spanning venture, growth, and public equities. Overlaps with Fairmount on biotech venture activity but operates at materially greater scale and breadth.

5Perceptive Advisors
TypeBroad incumbent
Description

Healthcare-dedicated investment firm investing across private and public biotech. Comparable sector focus and willingness to engage in PIPE/private placements like Fairmount's Mentari deal.

6Deerfield Management
TypeBroad incumbent
Description

Healthcare-focused investment manager with venture, private equity, and public strategies. Comparable in serving biotech companies across capital needs but at meaningfully larger scale.

7ARCH Venture Partners
TypeDirect peer
Description

Biotech-focused early-stage venture capital firm with deep therapeutic focus. Comparable in sector specialization and stage focus on therapeutic platform companies similar to Fairmount's portfolio.

8Atlas Venture
TypeDirect peer
Description

Biotech-focused early-stage venture capital firm building therapeutic companies from inception. Comparable in seed-to-Series A biotech investing and founder-led company creation similar to Korsana.

9TCGX
TypeDirect peer
Description

Healthcare-focused crossover fund that co-led Korsana's $150M Series A alongside Fairmount. Directly comparable as a biotech specialist participating in private financings of therapeutic developers.

10Wellington Management
TypeBroad incumbent
Description

Large global asset manager with deep healthcare investing capability that co-led Korsana's Series A. Comparable in ability to write large biotech checks but operates across a vastly broader investment universe.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment38 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fairmount Funds Management

Healthcare Venture Capital Investment Managementfairmountfunds.com

Fairmount Funds Management firmographics

Firmographics
Name
Fairmount Funds Management
Legal name
Fairmount Funds Management LLC
Website
https://fairmountfunds.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Fairmount Funds Management industry classification

Industry
Product category
Healthcare Venture Capital Investment Management
NAICS
Other Investment Pools and Funds (5259)
SIC
Finance Services (6199)
akta.pro primary industry
Venture Debt Providers (FSANAAAL)

Keywords

  • Biotechnology venture capital
  • Life science investing
  • Healthcare investment management
  • Therapeutic development funding
  • Clinical-stage equity financing

Where Fairmount Funds Management is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fairmount Funds Management business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Returns and Capital Gains: Generates returns through equity investments in biotechnology and life science companies, including venture capital funding rounds, public market investments, and strategic financing arrangements.

Fairmount Funds Management product offering

Product offering

Core offering

Fairmount Funds Management is a Philadelphia-based investment firm dedicated to providing venture capital and strategic financing to biotechnology and life science companies pursuing novel therapeutic treatments. The firm deploys capital through seed investments, private placements, Series A financings, and secondary-market share sales, while also engaging actively in portfolio governance through board representation and voting agreements supporting strategic transactions.

Product overview

Fairmount Funds Management is a Philadelphia-based investment firm that does not offer a technology product or service platform. It is dedicated to investing in promising new therapies pursued by biotechnology and life science companies, providing capital to support the development of therapeutic candidates across various stages of development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotechnology and life science venture capital investment services Equity capital deployment into clinical-stage and commercial-stage biotechnology and life science companies pursuing novel therapeutic treatments, provided to biotech issuers and their boards as direct equity investments through seed, private placement, Series A, and other structured financings.

Companies that use Fairmount Funds Management

Customer profile

Segments2 records

Ideal customer profiles1 record

Fairmount Funds Management technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Fairmount Funds Management partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Fairmount Funds Management competitors and assessment

Company assessment

Direct peers

  • Venrock Healthcare Capital Partners: Healthcare-focused venture capital firm that co-invested alongside Fairmount in co-founding Korsana Biosciences. Highly comparable as a biotech/life science specialist with similar investment stage and sector mandate.
  • RA Capital Management: Healthcare-focused crossover fund that invests across public and private biotech companies. Comparable in sector focus, ability to participate across financing stages, and lead private placements in therapeutic developers.
  • Baker Bros. Advisors: Biotech-focused long-only investment manager with deep life sciences specialization. Comparable in vertical focus on therapeutic developers and willingness to take concentrated, long-duration positions.
  • ARCH Venture Partners: Biotech-focused early-stage venture capital firm with deep therapeutic focus. Comparable in sector specialization and stage focus on therapeutic platform companies similar to Fairmount's portfolio.
  • Atlas Venture: Biotech-focused early-stage venture capital firm building therapeutic companies from inception. Comparable in seed-to-Series A biotech investing and founder-led company creation similar to Korsana.
  • TCGX: Healthcare-focused crossover fund that co-led Korsana's $150M Series A alongside Fairmount. Directly comparable as a biotech specialist participating in private financings of therapeutic developers.

Broad incumbents

  • OrbiMed Advisors: Large, established healthcare investment platform spanning venture, growth, and public equities. Overlaps with Fairmount on biotech venture activity but operates at materially greater scale and breadth.
  • Perceptive Advisors: Healthcare-dedicated investment firm investing across private and public biotech. Comparable sector focus and willingness to engage in PIPE/private placements like Fairmount's Mentari deal.
  • Deerfield Management: Healthcare-focused investment manager with venture, private equity, and public strategies. Comparable in serving biotech companies across capital needs but at meaningfully larger scale.
  • Wellington Management: Large global asset manager with deep healthcare investing capability that co-led Korsana's Series A. Comparable in ability to write large biotech checks but operates across a vastly broader investment universe.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Fairmount Funds Management social profiles

Digital presence

Fairmount Funds Management financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fairmount Funds Management leadership team

Management profile

Number of profiles

Profiles1 record

Fairmount Funds Management funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fairmount Funds Management M&A and investment

M&A and investment

M&A

Investments38 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fairmount Funds Management

What does Fairmount Funds Management do?

Fairmount Funds Management is a Philadelphia-based investment firm dedicated to providing venture capital and strategic financing to biotechnology and life science companies pursuing novel therapeutic treatments. The firm deploys capital through seed investments, private placements, Series A financings, and secondary-market share sales, while also engaging actively in portfolio governance through board representation and voting agreements supporting strategic transactions.

Is Fairmount Funds Management a public or private company?

Fairmount Funds Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Fairmount Funds Management founded?

Fairmount Funds Management was founded in -1. It employs 11 to 50 people.

Where is Fairmount Funds Management based?

Fairmount Funds Management is headquartered in Philadelphia, United States, in the North America region.

How does Fairmount Funds Management make money?

One revenue line is on record: investment Returns and Capital Gains.

Who are Fairmount Funds Management's main competitors?

Direct peers on record are Venrock Healthcare Capital Partners, RA Capital Management, Baker Bros. Advisors, ARCH Venture Partners, Atlas Venture and TCGX. Broad incumbents are OrbiMed Advisors, Perceptive Advisors, Deerfield Management and Wellington Management.

Does Fairmount Funds Management have an API?

No public API is recorded for Fairmount Funds Management.

What industry is Fairmount Funds Management in?

Fairmount Funds Management's product category is Healthcare Venture Capital Investment Management. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers. Its NAICS code is 5259 and its SIC code is 6199.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioPharma DiveA booming business on Wall Street would love more biotechs to quietly dieBiotech reverse mergers are booming, with roughly 24 announced this year, more than double the 10 seen in 2025. Fairmount Funds has helped about half a dozen deals, raising $2 billion in private financing. Demand may outstrip supply of quality shells, potentially slowing the trend.BioSpaceMentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention PipelineMentari Therapeutics announced a $200 million private placement to leading healthcare investors, with proceeds extending cash runway into 2029 and supporting Phase 2a readouts on its PACAP-targeted lead programs. The financing is expected to close before the merger with InMed Pharmaceuticals, which will continue operating under the Mentari name.STATAkero team, backed by Fairmount, launches new immunology companyThe former Akero Therapeutics team, backed by Fairmount, launched Avere Therapeutics, a publicly traded biotech. The company will develop an oral IL-23 targeted drug for psoriasis, ulcerative colitis, and other immunological conditions. The team previously developed a MASH drug sold to Novo for $5 billion.BioSpaceNextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 TherapyNextCure and Avere Therapeutics announced a definitive all-stock merger to advance Avere's oral IL-23 therapy AVR-001. The deal includes a $320 million private placement and is expected to close in the second half of 2026, with the combined company trading as AVRX. The financing is expected to fund development through Phase 2b readout and initiate Phase 3 trials.The Pharma LetterMentari lists via InMed merger, takes $290m for migraine pipelineInMed Pharmaceuticals will merge with Mentari Therapeutics in an all-stock reverse merger, creating a Nasdaq-listed migraine-prevention company. The deal values the combined firm at about $421 million, including a $290 million private financing led by Fairmount, with InMed shareholders owning roughly 1.5%.Defense WorldZenas BioPharma (NASDAQ:ZBIO) Director Fairmount Funds Management Llc Acquires 150,000 SharesZenas BioPharma Director Fairmount Funds Management LLC acquired 150,000 shares of the company on March 31st at $20.00 per share, totaling $3,000,000, which increased the director's stake by 6.79% to 2,359,025 shares valued at $47,180,500. The company recently reported Q earnings of ($4.54) per share, missing the consensus estimate of ($1.22) by $3.32. Hedge funds including SR One Capital Management, NEA Management Company, and Federated Hermes increased their positions in Zenas BioPharma during Q4, while analysts maintain a consensus "Hold" rating with a $44.14 price target.Investing.comTuesday’s insider activity: CEO doubles down on biotech stock By Investing.comThis article reports on insider buying and selling activity across multiple U.S. public companies on March 31, 2026, highlighting significant purchases by CEOs and directors in companies including Zenas BioPharma, Navan, Immunome, and Cross Timbers Royalty Trust, alongside notable sales by major shareholders and executives in companies such as Cognex, Ingram Micro, Archrock, and United Therapeutics. Key transactions include CEO Leon Moulder acquiring 54,000 shares of Zenas BioPharma for $1.02 million as the stock declined 46% year-to-date, while Fairmount Funds Management sold 7 million shares of Cognex for approximately $242.6 million. The roundup covers insider activity across at least eight companies, including several transactions involving ten-percent owners and executive leadership.FierceBiotechParagon spinout Jade casts reverse merger spell with AerovateJade Biosciences has entered a reverse merger with Aerovate Therapeutics, allowing Jade to list on the Nasdaq under the ticker 'JBIO' while retaining its name and leadership. The deal involves a $65 million dividend paid by Aerovate to its shareholders prior to closing in early 2025, supported by a $300 million private investment led by Fairmount. The combined entity will use these funds to advance Jade's autoimmune disease pipeline, specifically moving its lead candidate JADE-001 into clinical trials.Qq8000万美元！新锐开发潜在“best-in-class”自身免疫疾病疗法_腾讯新闻Jade Biosciences has secured $80 million in funding led by Fairmount and Venrock Healthcare Capital Partners to support the development of targeted therapies for inflammation and immunity. The company's lead candidate is a potential 'best-in-class' biopharmaceutical therapy for autoimmune diseases, which was designed by Paragon Therapeutics.MoomooYushi Biological invested 80 million US dollars to conduct pioneering research on therapies for autoimmune diseases.Jade Biosciences announced the closing of an $80 million financing round led by Fairmount and Venrock Healthcare Capital Partners to develop therapies for autoimmune diseases. The company, which is the fourth spin-off from Paragon Therapeutics, has appointed Andrew King as its Chief Scientific Officer to lead preclinical development efforts. This funding supports Jade's mission to deliver potentially best-in-class treatments for inflammation and immunology indications.